Oct 16, 2023

Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023

We are delighted to announce that Aitia will be at the Clinical Trials on Alzheimer’s Disease conference (CTAD) being held from October 24-27 in Boston, MA.

We will be presenting a poster focused on prediction of Amyloid PET positivity of Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on blood-based biomarkers and clinical data discovered.

Details of the abstract and poster presentation are as follow:

Poster #82769

Abstract #00362

Theme: Clinical Trials: Biomarkers including plasma

Presentation Title: Prediction of Amyloid PET positivity from blood-based biomarkers and clinical data using AI-based Digital Twins

Information about CTAD 2023 can be found at https://www.ctad-alzheimer.com/